Patient Empowerment Program: A Rare Disease Podcast

n-Lorem Foundation (Dr. Stan Crooke, Amy Williford, Kim Butler, Andrew Serrano, Jon Magnuson, and Kira Dineen)
  • 5.0 (29)
  • LIFE SCIENCES
Patient Empowerment Program: A Rare Disease Podcast

Join the nano-rare disease community! Interviews features leading physicians, scientists, biotech experts, and patient advocates. Lessons teach core concepts about drugs. Our host Dr. Crooke has led the creation of antisense technology and his foundation, n-Lorem, is using this powerful technology to discover, develop, and provide personalized experimental antisense oligonucleotide medicines to nano-rare patients for free, for life. n-Lorem is a non-profit organization established to apply the efficiency, versatility and specificity of antisense technology to charitably provide experimental antisense oligonucleotide (ASO) medicines to treat patients (less than 30 patients) that are the result of a single genetic defect unique to only one or very few individuals. The advantage of experimental ASO medicines is that they can be developed rapidly, inexpensively and are highly specific. n-Lorem was founded by Dr. Stan Crooke, who founded IONIS Pharmaceuticals in 1989 and, through his vision and leadership, established the company as the leader in RNA-targeted therapeutics. The podcast is produced by n-Lorem Foundation and hosted by Dr. Stanley T. Crooke, who is the Founder, CEO and Chairman. Our videographer is Jon Magnuson. Our producers are Kira Dineen, Jon Magnuson, Andrew Serrano, and Amy Williford. To learn more about n-Lorem, visit nlorem.org. Contact us at podcast@nlorem.org.

  1. Q&A - 2024 Nano-rare Patient Colloquium Recap

    3 DAYS AGO

    Q&A - 2024 Nano-rare Patient Colloquium Recap

    Join Stan Crooke, n-Lorem founder, CEO, and host of the Patient Empowerment Program Podcast, alongside Amy Williford, Sr. Director of Communications and Donor Relations, for a special episode. In this post-colloquium Q&A, Stan recaps the 2024 Nano-rare Patient Colloquium and the progress n-Lorem has made as the organization nears its 5-year anniversary, shares his candid reflections on the event, and dives into additional thoughts and questions that weren’t covered. Do you have additional questions? Email podcast@nlorem.org.   Question Bank: 2:15 How do you think the event went this year? 6:05 Were observations of benefit expected in patients so quickly?  9:47 What do you expect the number of patients treated to be next year? 10:57 Do you have a message to supporters? 12:30 Were there any disappointments from the colloquium? 13:21 What are the most important things that n-Lorem has learned this year?  16:13 Do you think n-Lorem’s processes will be outlined every year at the event? 18:05 How is AI incorporated at n-Lorem? 19:10 Does your recently announced deal with GondolaBio reflect the sustainability strategy discussed at the event? 20:53 n-Lorem is celebrating 5 years in 2025. Did you expect the foundation to be where it is today? 21:28 Does n-Lorem plan to expand into Europe and elsewhere?   Make hope possible with a donation.

    24 min

  2. DEC 4

    Best of the 2024 Nano-rare Patient Colloquium

    This year’s Colloquium spanned two perfect autumn days in beautiful Cambridge, Massachusetts where hundreds of nano-rare community members from around the world gathered under a single roof to learn, connect, and support one another. We’re pleased to announce that the event welcomed over 750 attendees, both in-person and virtually. It’s each and every one of you who made the event such a success! For this special episode, we gathered the ‘Best’ clips from the event for you to learn from and enjoy. To submit questions for our upcoming Q&A episode, email podcast@nlorem.org. We can’t wait to hear from you!2024 Colloquium Recap On this episode: 2:07 Daphne Graskewicz-Prado, ASO The Perilous Journey to Diagnosis and Treatment for Nano-rare 9:35 Ryan Strankowski and Dr, Nelson Leung, Ryan’s Journey and Clinical Experience 15:55 Luke Rosen, Megan Hedstrom, and Dr. Jennifer Bain, Susannah’s & Sloane’s Journeys and Unique Clinical Experiences 21:49 Kelley Dalby and Dr. Olivia Kim-McManus, Connor’s Journey and Clinical Experience 30:00 Dr. Julie Ziobro and Dr. Horacio Kaufmann, Building a Nano-rare Network and Managing Institutional Challenges 37:38 Dr. Andrew Lo and Dr. Alan Lotvin, Innovative Ways to Support Nano-rare 42:30 Dr. Toby Ferguson, Dr. Liz Berry-Kravis, and Dr. Eugene Shneider, Changing the World One Patient at a Time 47:30 Dr. Kate Dawson, What It Means to be a Parter with n-Lorem for Nano-rare 50:23 Dr. Stanley Crooke, Providing Hope for a Better Future, One Nano-rare Patient at a Time

    58 min
  3. Susannah's Progress: Two Years of ASO Treatment with Dr. Jennifer Bain and Luke Rosen

    OCT 16

    Susannah's Progress: Two Years of ASO Treatment with Dr. Jennifer Bain and Luke Rosen

    Two years of treatment—two years of strength, courage, and blazing a trail for other nano-rare patients! 🎉 Susannah's story was the first shared on the Patient Empowerment Program podcast. Now, two years later, her father, Luke Rosen, and her physician, Dr. Jennifer Bain, detail Susannah’s remarkable progress since beginning regular treatments—highlighting improvements in her motor skills, cognition, energy, and more! Susannah's Story (May 25, 2022) Donate 2024 Nano-rare Patient Colloquium   On This Episode We Discuss: 3:10 Susannah's KIF1A mutation 5:50 Luke and his wife Sally changed their careers to help find a treatment for KIF1A 7:23 How Susannah's family first heard of n-Lorem 8:43 Jen on the Columbia University Medical Center team and the decision to treat Susannah 12:25 Luke's experience bringing his daughter to receive an experimental ASO treatment for the first time 14:30 The positive outcomes and observations of Susannah's treatment 26:15 What Dr. Bain has learned since treating Susannah 29:15 Luke on the impact and importance of the little things 31:15 Advice to other parents 35:40 Being part of a community of nano-rare patients and families

    41 min

  4. OCT 2

    Sneak Peek of the 2024 Nano-rare Patient Colloquium

    Take a glimpse behind the curtain as we offer you a sneak peek of the 2024 Nano-rare Patient Colloquium. We’re thrilled to welcome back longtime biotech journalist and current Features Editor of The Transmitter, Brady Huggett, to the podcast. In an interview with n-Lorem founder and CEO Stan Crooke, they preview the upcoming Colloquium, diving into key topics that will shape the conversation at the event and around nano-rare diseases in the year ahead.On This Episode We Discuss: 2:21 How many Investigational New Drugs (INDs) has n-Lorem filed?  5:22 How many patients treated with an n-Lorem ASO have been on therapy long enough to observe a benefit?  6:50 What does it mean for a patient like Susannah who has experienced a significant decrease in behavioral arrest incidents since receiving treatment  9:39 Providing ASOs to patients earlier  13:25 INDs for the ‘n-of-few'  23:15 Introducing Whole Genome Sequencing (WGS) for all newborns  29:05 Stan’s perspective on leadership  33:50 n-Lorem's goals for the 2024 Nano-rare Patient Colloquium Register for the 2024 Nano-rare Patient Colloquium Donate Biogen.com

    42 min
  5. The Building Blocks of What's Possible with David Butler, Ph.D.

    SEP 18

    The Building Blocks of What's Possible with David Butler, Ph.D.

    Hongene Biotech is a producer of RNA building blocks – the first step for what’s possible in RNA drug-discovery and development. David Butler, Ph.D., Chief Technology Officer of Hongene, joins the Patient Empowerment Program to discuss why Hongene aims to help make RNA medicines accessible and affordable for patients everywhere, regardless of prevalence.   On this episode we discuss: 2:40 Hongene Biotech and what do they do 8:09 The early days of nucleoside building blocks and maturation of Hongene 12:00 Hongene is a strong supporter of n-Lorem. Why? 15:30 David’s origins in the chemistry field 17:38 Incremental progress that has been made in science and manufacturing   Links: 2024 Colloquium - https://www.nlorem.org/nano-rare-patient-colloquium-2024/ Make Hope Possible with a Donation - https://www.nlorem.org/donate/ Hongene - https://www.hongene.com/

    30 min
  6. Knowledge is Power: Part 2

    SEP 3

    Knowledge is Power: Part 2

    The concluding episode of the Knowledge is Power series. The knowledge we are gaining at n-Lorem has even more value than benefiting nano-rare patients and their families. These insights will enable scientists to discover new therapeutic targets for both common and rare diseases, fundamentally changing the way we approach health and disease. Survey – Patient Empowerment Program Podcast Register for the 2024 Nano-rare Patient Colloquium   On This Episode We Discuss: Questions we can answer and teach us about health and disease and opportunities to treat more common diseases What are all the functions of human genes? Are there gene products that have redundant functions? Do identical mutations cause identical phenotypes? n-Lorem can demonstrate that ASOs work on general types of disease challenges

    30 min
  7. Knowledge is Power: Part 1

    AUG 21

    Knowledge is Power: Part 1

    The knowledge we are gaining at n-Lorem has even more value than benefiting nano-rare patients and their families. These insights will enable scientists to discover new therapeutic targets for both common and rare diseases, fundamentally changing the way we approach health and disease.Survey – Patient Empowerment Program PodcastRegister for the 2024 Nano-rare Patient ColloquiumOn This Episode We Discuss:Two most common words in medicine: Health and DiseaseThe Scientific MethodThe Importance of Single VariablesOrthogonal ThinkingWe Are at a Unique Moment in Medical HistoryGenomicsAdvances in OmicsBiological Networks and AIFacile Collection, Maintenance, Growth and Differentiation in the LabAntisense Technology

    35 min
  8. Adopting a Rare Son with Paul Compton

    AUG 7

    Adopting a Rare Son with Paul Compton

    Paul Compton and his wife Andrea chose to start a family through adoption. Unknown to anyone, one of their adopted boys, Taeson, was the inheritor of DRPLA, a progressive brain disorder caused by a mutation in the ATN1 gene. Determined to find a treatment and advocate for their son and others with the disease, the Comptons established CureDRPLA. In early 2024, Taeson received his initial treatment with an ASO discovered and developed by n-Lorem. Paul discusses his family’s journey and shares his observations of Taeson's progress since beginning treatment.In This Episode We Discuss:3:05 – Paul's origins in business and finance 4:32 - Investment banking is different than traditional banking 7:27 – Opposites attract – Meeting his wife, Andrea, and starting a family through adoption 10:06 – Paul’s son, Tayson, has a progressive brain disorder known as DRPLA, which is caused by a mutation in the ATN1 gene; Discovering the idea of n-Lorem 16:03 – Tayson’s journey to a diagnosis 23:00 – The deterioration of his abilities over the years 25:00 – The progress Paul has observed in his son since initial treatment Links:Take our survey and receive an n-Lorem Store coupon code Register for the 2024 Nano-rare Patient Colloquium / October 30-31, 2024Make Hope Possible with a donation

    34 min
See All (65)

Trailer

5
out of 5
29 Ratings

About

Join the nano-rare disease community! Interviews features leading physicians, scientists, biotech experts, and patient advocates. Lessons teach core concepts about drugs. Our host Dr. Crooke has led the creation of antisense technology and his foundation, n-Lorem, is using this powerful technology to discover, develop, and provide personalized experimental antisense oligonucleotide medicines to nano-rare patients for free, for life. n-Lorem is a non-profit organization established to apply the efficiency, versatility and specificity of antisense technology to charitably provide experimental antisense oligonucleotide (ASO) medicines to treat patients (less than 30 patients) that are the result of a single genetic defect unique to only one or very few individuals. The advantage of experimental ASO medicines is that they can be developed rapidly, inexpensively and are highly specific. n-Lorem was founded by Dr. Stan Crooke, who founded IONIS Pharmaceuticals in 1989 and, through his vision and leadership, established the company as the leader in RNA-targeted therapeutics. The podcast is produced by n-Lorem Foundation and hosted by Dr. Stanley T. Crooke, who is the Founder, CEO and Chairman. Our videographer is Jon Magnuson. Our producers are Kira Dineen, Jon Magnuson, Andrew Serrano, and Amy Williford. To learn more about n-Lorem, visit nlorem.org. Contact us at podcast@nlorem.org.

Information

  • Creator
    n-Lorem Foundation (Dr. Stan Crooke, Amy Williford, Kim Butler, Andrew Serrano, Jon Magnuson, and Kira Dineen)
  • Years Active
    2022 - 2024
  • Episodes
    65
  • Rating
    Clean
  • Copyright
    © Copyright 2024 n-Lorem Foundation
  • Show Website
    Patient Empowerment Program: A Rare Disease Podcast

You Might Also Like

To listen to explicit episodes, sign in.

Stay up to date with this show

Sign in or sign up to follow shows, save episodes, and get the latest updates.
Select a country or region

Africa, Middle East, and India

Asia Pacific

Europe

Latin America and the Caribbean

The United States and Canada